Literature DB >> 6473105

Characterization of an adduct between CC-1065 and a defined oligodeoxynucleotide duplex.

D R Needham-VanDevanter, L H Hurley, V L Reynolds, N Y Theriault, W C Krueger, W Wierenga.   

Abstract

CC-1065 is a potent antitumor antibiotic produced by Streptomyces zelensis. The drug binds covalently through N-3 of adenine and lies within the minor groove of DNA. Previous studies indicated that CC-1065 reacted with adenine in DNA to yield a thermally labile product that could be used to reveal its sequence specificity. These studies also provided insight into a DNA sequence (5'-CGGAGTTAGGGGCG-3') which should bind one molecule of CC-1065 in an unambiguous manner. This sequence, which contains the CC-1065 adenine binding site within the sequence 5'-TTA-3' was chemically synthesized together with the complementary strand. CC-1065 reacted with the oligoduplex to give an adduct that maintained the B-DNA form and had a final CD spectrum similar to those of the CC-1065 complexes formed with calf thymus DNA. The above 14mer was 5' end-labelled with 32P, annealed with its complementary strand, reacted with CC-1065 and heated. Drug-mediated strand breakage was evaluated on a sequencing gel. A single break occurred in the labelled strands to give a fragment that migrated as an 8.5mer; subsequent piperidine treatment produced a fragment that migrated as a 7mer, which is the size expected from the known binding of CC-1065 at adenine in 5'-TTA-3' sequences.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6473105      PMCID: PMC320064          DOI: 10.1093/nar/12.15.6159

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  5 in total

Review 1.  Mechanism of bleomycin action: in vitro studies.

Authors:  R M Burger; J Peisach; S B Horwitz
Journal:  Life Sci       Date:  1981-02-16       Impact factor: 5.037

2.  An efficient method for the sequence analysis of oligodeoxyribonucleotides.

Authors:  A M Banaszuk; K V Deugau; J Sherwood; M Michalak; B R Glick
Journal:  Anal Biochem       Date:  1983-02-01       Impact factor: 3.365

3.  Mechanism of interaction of CC-1065 (NSC 298223) with DNA.

Authors:  D H Swenson; L H Li; L H Hurley; J S Rokem; G L Petzold; B D Dayton; T L Wallace; A H Lin; W C Krueger
Journal:  Cancer Res       Date:  1982-07       Impact factor: 12.701

4.  CC-1065 (NSC 298223), a novel antitumor agent that interacts strongly with double-stranded DNA.

Authors:  L H Li; D H Swenson; S L Schpok; S L Kuentzel; B D Dayton; W C Krueger
Journal:  Cancer Res       Date:  1982-03       Impact factor: 12.701

5.  CC-1065 (NSC 298223), a most potent antitumor agent: kinetics of inhibition of growth, DNA synthesis, and cell survival.

Authors:  B K Bhuyan; K A Newell; S L Crampton; D D Von Hoff
Journal:  Cancer Res       Date:  1982-09       Impact factor: 12.701

  5 in total
  2 in total

1.  Theoretical study of the sequence specificity in the covalent binding of the antitumor drug CC-1065 to DNA.

Authors:  K Zakrzewska; M Randrianarivelo; B Pullman
Journal:  Nucleic Acids Res       Date:  1987-07-24       Impact factor: 16.971

2.  Finding potential DNA-binding compounds by using molecular shape.

Authors:  P D Grootenhuis; D C Roe; P A Kollman; I D Kuntz
Journal:  J Comput Aided Mol Des       Date:  1994-12       Impact factor: 3.686

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.